Zeltia

Zeltia was a Spanish pharmaceutical and chemical group founded in Vigo in 1939 as a spin-off from the Miguel Servet laboratory. Its early development was driven by the Fernández López brothers of Lugo, whose business interests included meat-processing operations in Porriño and Mérida, and by scientific contributors including Fernando Calvet Prats. The company emerged from research into medicinal plants, animal-gland products and the extraction of ergot alkaloids, substances used in medicines such as the migraine and glaucoma treatment Pan-Ergot. Its founding context was closely connected to the scientific and political disruption caused by the Spanish Civil War and the Franco period. Calvet had been associated with the Miguel Servet laboratories and later experienced political repression before returning to academic work; his technical knowledge helped shape Zeltia's initial laboratory and extraction activities. The company's original ambition was to use Spain's medicinal flora and biological materials as the basis for pharmaceutical products. Over time, Zeltia developed into a group structure combining pharmaceutical research, chemical businesses, veterinary products, pest-control products, wood-protection materials and genomics. The group operated through subsidiaries rather than as a single focused consumer-facing brand. Businesses associated with the group included PharmaMar, Genómica, Zelnova, Protección de Maderas, Xylazel, Noscira and Sylentis, together with international subsidiaries of PharmaMar and the Italian company Copyr through Zelnova. Zeltia's pharmaceutical research was strategically important but commercially difficult. Reference material stated that, as of 2007, its pharmaceutical research activities had not yet produced a marketed product. The group structure and governance also reduced some of the short-term pressure usually placed on research-led companies: the majority shareholder and chairman were described as being the same person. Zeltia consequently represented a diversified research and chemicals holding group whose value depended on long development cycles, subsidiary businesses and the eventual success of pharmaceutical programs. The company progressively separated or sold parts of its historical operating portfolio. In 1993 it sold Cooper-Zeltia, which subsequently took the name CZ Veterinaria and was later renamed Zendal. In the late 2010s, Zeltia's portfolio was further reduced through the disposal of Xylazel and Zelnova. In 2018 PharmaMar sold Xylazel to AkzoNobel, and in 2019 PharmaMar sold Zelnova, described in the reference material as the group's last subsidiary in Galicia, to the Galician investment company Allentia Invest for €33 million. Zeltia was ultimately taken over by its subsidiary PharmaMar in a reverse takeover, while the group structure was retained during that transaction. It is therefore best treated as a former corporate group rather than an active standalone brand.

Zeltia was established in Vigo in 1939 as a spin-off from the Miguel Servet laboratory. The founding initiative was associated principally with the Fernández López brothers, four brothers from Lugo who were active in businesses connected with slaughterhouses and meat processing in Porriño and Mérida. Scientific support came from Fernando Calvet Prats, who had worked with the Miguel Servet laboratories in Vigo and brought expertise in the preservation, analysis and extraction of ergot from rye. Ergot was a source of alkaloids used in medicines, including Pan-Ergot, which was indicated for migraines and glaucoma. The company's formation reflected the difficult scientific and political circumstances of Spain after the Civil War. Calvet had been politically repressed by the Franco regime and had spent time in Sweden before returning to Spain. Dr. Obella Vidal, who was connected with the earlier laboratory work and with pharmacist Rubira, also played a role in the business's prehistory. A Zeltia trademark was registered in Portugal in 1937 in connection with ergot exploitation, before the company's formal establishment in 1939. The Fernández López brothers supplied the commercial and industrial base, while Calvet and other scientists helped organize the laboratory and define its technical objectives. Zeltia initially sought to exploit Spain's medicinal flora and substances derived from animal glands. Its relationships with meat-processing businesses gave the company access to biological raw materials, while its laboratory activities aimed to turn those materials into pharmaceutical ingredients and products. Over the following decades it expanded from its original pharmaceutical and biochemical focus into a broader group of pharmaceutical, chemical, veterinary, pest-control, wood-protection and biotechnology businesses. The group later operated through a network of subsidiaries. Those identified as direct subsidiaries around 2009 included Pharma Mar, Genómica, Zelnova, Protección de Maderas, Xylazel, Noscira and Sylentis. PharmaMar also had international subsidiaries in the United States, Switzerland, France, Germany and the United Kingdom. Copyr, an Italian company, was identified as an indirect subsidiary through Zelnova. This structure allowed Zeltia to combine early-stage pharmaceutical research with businesses that served more established chemical and biological product markets. Pharmaceutical research remained central to the group's long-term identity, but it involved substantial uncertainty. Reference material stated that by 2007 Zeltia's pharmaceutical research activities had not produced a marketed product. The company's governance structure was unusual in that its majority shareholder and chairman were described as the same person, a concentration that reduced the immediate earnings pressure often faced by research-intensive companies. Zeltia also disposed of several historical operating businesses. In 1993 it sold Cooper-Zeltia, which became CZ Veterinaria and was later renamed Zendal. In 2018 PharmaMar sold Xylazel to AkzoNobel. In 2019 PharmaMar sold Zelnova to Allentia Invest for €33 million. These transactions reduced the presence of the former group in traditional chemical and industrial product categories. The corporate endpoint of Zeltia came through a reverse takeover by its subsidiary PharmaMar. Although the group's structure was retained during the transaction, Zeltia ceased to function as the principal standalone corporate identity. Its historical legacy therefore survives mainly through successor and former subsidiary businesses, especially PharmaMar and the companies that developed from the group's veterinary, pest-control and wood-protection operations.

• 2019

  Zelnova sold to Allentia Invest

  [1]Zeltiaen.wikipedia.org

  PharmaMar sold Zelnova to Allentia Invest for €33 million.

• 2018

  Xylazel sold to AkzoNobel

  [1]Zeltiaen.wikipedia.org

  PharmaMar sold the wood-protection company Xylazel to AkzoNobel.

• 2009

  Broad subsidiary portfolio documented

  [1]Zeltiaen.wikipedia.org

  The group was described as operating through pharmaceutical, genomics, veterinary, pest-control, wood-protection and biotechnology subsidiaries, including Pharma Mar, Genómica, Zelnova, Xylazel, Noscira and Sylentis.

• 2007

  Pharmaceutical research had not yet produced a marketed product

  [1]Zeltiaen.wikipedia.org

  Reference material reported that Zeltia's pharmaceutical research activities had not resulted in a marketed product by this point.

• 1993

  Cooper-Zeltia is sold

  [1]Zeltiaen.wikipedia.org

  Zeltia sold Cooper-Zeltia. The subsidiary later became CZ Veterinaria and was subsequently renamed Zendal.

• 1939

  Zeltia founded in Vigo

  [1]Zeltiaen.wikipedia.org

  Zeltia was founded in Vigo as a spin-off from the Miguel Servet laboratory, with the Fernández López brothers as the principal commercial force and Fernando Calvet Prats among its scientific contributors.

• 1937

  Zeltia name registered in Portugal in connection with ergot

  [1]Zeltiaen.wikipedia.org

  A Zeltia trademark was registered in Portugal in connection with the exploitation of ergot before the company's formal establishment.

• PharmaMar completes a reverse takeover of Zeltia

  [1]Zeltiaen.wikipedia.org

  Zeltia was taken over by its subsidiary PharmaMar in a reverse takeover, marking the end of Zeltia as the principal standalone corporate identity.

A Spanish research-led pharmaceutical and chemicals group built around biological materials, specialty chemicals and a portfolio of operating subsidiaries. Its identity combined pharmaceutical innovation with veterinary, pest-control, wood-protection and biotechnology businesses.

• Pharmaceuticals

  Ergot-derived pharmaceutical products

  Zeltia's origins were linked to laboratory work on preserving, analyzing and extracting ergot from rye. The resulting alkaloids were used in pharmaceutical manufacturing, including the medicine Pan-Ergot, associated with treatment for migraines and glaucoma. This early activity illustrates the company's original emphasis on converting biological materials and medicinal flora into pharmaceutical applications.

• Animal health

  Veterinary products

  Veterinary activities were represented by Cooper-Zeltia, which Zeltia sold in 1993. The business subsequently operated as CZ Veterinaria and later adopted the name Zendal. It formed part of the group's broader move from its original pharmaceutical chemistry base into applied biological and animal-health markets.

• Specialty chemicals

  Pest-control products

  Zelnova and its indirect subsidiary Copyr represented the group's pest-control activities. These businesses extended Zeltia's chemical and biological expertise into products for pest management. Zelnova was sold in 2019, ending the former group's direct association with this part of the portfolio.

• Wood-care chemicals

  Wood-protection products

  Xylazel and Protección de Maderas were the group's identified wood-protection businesses. They represented an industrial chemicals line distinct from Zeltia's pharmaceutical research activities. Xylazel was sold to AkzoNobel in 2018.

• Biotechnology

  Pharmaceutical and biotechnology research

  PharmaMar, Genómica, Noscira and Sylentis were among the group companies associated with pharmaceutical research, genomics and biotechnology. The research portfolio was central to Zeltia's long-term strategy, although reference material stated that its pharmaceutical research had not produced a marketed product as of 2007.

• 2019

  Sale of Zelnova to Allentia InvestM&A

  Background

  Zelnova was identified as the group's last subsidiary in Galicia and formed part of the remaining traditional chemical portfolio.

  Action taken

  PharmaMar sold Zelnova to Allentia Invest for €33 million.

  Aftermath

  The disposal removed another major chemical operating business from the former Zeltia group.

  Sale price. €33 million transaction value (2019)

  Source

• 2018

  Sale of Xylazel to AkzoNobelM&A

  Background

  The former Zeltia group was reducing and reshaping its portfolio of traditional chemical businesses.

  Action taken

  PharmaMar sold Xylazel to AkzoNobel.

  Aftermath

  Xylazel moved into the AkzoNobel group, further separating the wood-protection business from the Zeltia successor structure.

  Source

• 1993

  Divestment of Cooper-ZeltiaM&A

  Background

  Zeltia was managing a diversified portfolio that included pharmaceutical, veterinary and chemical businesses.

  Action taken

  The company sold Cooper-Zeltia, which later operated as CZ Veterinaria and then Zendal.

  Aftermath

  The transaction separated the veterinary business from Zeltia while preserving its later development under successor names.

  Source

• Reverse takeover by PharmaMarM&A

  Background

  PharmaMar had become the strategically important pharmaceutical subsidiary within the broader Zeltia group.

  Action taken

  PharmaMar took over Zeltia through a reverse takeover while retaining the group structure.

  Aftermath

  Zeltia ceased to operate as the principal standalone corporate identity and the successor structure became centered on PharmaMar.

  Source

1. 1Zeltiaen.wikipedia.org